Ra Pharmaceuticals Inc

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%



Code Company Date Close Change Indicator Value Signal

Trading Performance

Chaikin Money Flow



Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 27 17.0 0.63% 1.31% 8.8% -3.0% 110.2%
SHORT 26 11.2 0.35% 0.53% 4.0% -7.2% -86.3%


Technical Analysis

Ra Pharmaceuticals Inc (RARX)



Developed by Marc Chaikin, Chaikin Money Flow measures the amount of Money Flow Volume over a specific period. Money Flow Volume forms the basis for the Accumulation Distribution Line. Instead of a cumulative total of Money Flow Volume, Chaikin Money Flow simply sums Money Flow Volume for a specific look-back period, typically 20 or 21 days. The resulting indicator fluctuates above/below the zero line just like an oscillator. Chartists weigh the balance of buying or selling pressure with the absolute level of Chaikin Money Flow. Chartists can also look for crosses above or below the zero line to identify changes on money flow.

Calculation: Chaikin Money Flow (20):
1) Money Flow Multiplier = [(Close - Low) - (High - Close)] / (High - Low);
2) Money Flow Volume = Money Flow Multiplier x Volume for the Period;
3) 20-period CMF = 20-period Sum of Money Flow Volume / 20 period Sum of Volume;

PROFILE: Ra Pharmaceuticals Inc (RARX)

Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |

About Ra Pharmaceuticals Inc: NASDAQ

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Top 10:

Chaikin Money Flow

Company Close Change(%) Volume Value Signal
NVAX Novavax Inc 5.74 20.1 9,559,800 0.21 BULLISH
LSCC Lattice Semicond 23.34 9.7 7,172,000 0.15 BULLISH
BLCM Bellicum Pharma 2.29 9 8,624,000 0.15 BULLISH
CCXI Chemocentryx 43.66 6.7 1,423,300 0.21 BULLISH
WING Wingstop 93.32 6.5 833,300 0.01 BULLISH
EPZM Epizyme Inc 26.72 4.6 1,255,600 0.33 BULLISH
ADRO Aduro Biotech 1.4 4.5 927,400 0.25 BULLISH
QCOM Qualcomm Inc 95.91 4.5 23,694,300 0.05 BULLISH
ATRC Atricure Inc 38.25 4.1 790,500 0.17 BULLISH
MERC Mercer Intl Inc 13.25 3.7 299,000 0.11 BULLISH